1. Executive Summary 2. United States Influenza Vaccines Market Size & Analysis (2013 - 2027) 3. United States Number of Persons Vaccinated with Influenza Vaccines (2013 - 2027) 3.1 Number of Children Vaccinated with Influenza Vaccines 3.2 Number of Adults Vaccinated with Influenza Vaccines 4. Key Drivers and Inhibitors of the United States Influenza Vaccines Market 4.1 Market Drivers 4.2 Market Restraints 5. United States Influenza Vaccines Pricing Trends & Analysis 6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies) 7. United States Influenza Vaccines Distribution & Demand (2010 - 2020) 8. Effectiveness of Influenza Vaccines in the United States (2004 – 2020) 9. Rapid Diagnostic Testing for the Management of Influenza 10. Distribution Channel & Technique of Influenza Vaccination in the United States 11. Reimbursement Environment of the United States Influenza Vaccines Market 12. Regulatory Framework of the United States Influenza Vaccines Market 13. Major Deals and Agreement Happenings in the Influenza Vaccines Market 13.1 Merger & Acquisitions 13.2 Collaboration Deal 13.3 Licensing Agreement 13.4 Exclusive Agreement 13.5 Distribution Agreement 14. Promising Influenza Vaccines in the Clinical Development 15. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country 15.1 Year 2020 15.2 Year 2019 16. Key Players Analysis 16.1 Sanofi Pasteur 16.1.1 Business Overview 16.1.2 Influenza Vaccines Portfolio 16.1.3 Influenza Vaccines Sales Value Analysis 16.1.4 Promising Influenza Vaccines in the Clinical Development 16.1.5 Recent Development 16.2 GlaxoSmithKline (GSK) 16.2.1 Business Overview 16.2.2 Influenza Vaccines Portfolio 16.2.3 Influenza Vaccines Sales Value Analysis 16.2.4 Recent Development 16.3 Seqirus 16.3.1 Business Overview 16.3.2 Influenza Vaccines Portfolio 16.3.3 Influenza Vaccines Sales Value Analysis 16.3.4 Promising Influenza Vaccines in the Clinical Development 16.3.5 Recent Development 16.4 AstraZeneca 16.4.1 Business Overview 16.4.2 Influenza Vaccines Portfolio 16.4.3 Influenza Vaccines Sales Value Analysis 16.4.4 Recent Development 17. Emerging Players Analysis 17.1 Novavax 17.1.1 Business Overview 17.1.2 Promising Influenza Vaccines in the Clinical Development 17.1.3 Recent Development 17.2 BiondVax Pharmaceuticals Ltd. 17.2.1 Business Overview 17.2.2 Promising Influenza Vaccines in the Clinical Development 17.2.3 Recent Development 17.3 Medicago 17.3.1 Business Overview 17.3.2 Promising Influenza Vaccines in the Clinical Development 17.3.3 Recent Development 17.4 Moderna Inc 17.4.1 Business Overview 17.4.2 Promising Influenza Vaccines in the Clinical Development 17.4.3 Recent Development 17.5 Pneumagen 17.5.1 Business Overview 17.5.2 Promising Influenza Vaccines in the Clinical Development 17.5.3 Recent Development 17.6 Altimmune 17.6.1 Business Overview 17.6.2 Promising Influenza Vaccines in the Clinical Development 17.6.3 Recent Development 17.7 Daiichi Sankyo 17.7.1 Business Overview 17.7.2 Promising Influenza Vaccines in the Clinical Development 17.7.3 Recent Development 17.8 FluGen 17.8.1 Business Overview 17.8.2 Promising Influenza Vaccines in the Clinical Development 17.8.3 Recent Development 17.9 Imutex 17.9.1 Business Overview 17.9.2 Promising Influenza Vaccines in the Clinical Development 17.9.3 Recent Development

List of Tables: Table 5–1: United States Pediatric Influenza Vaccines Price, 2020 – 2021 Table 5–2: United States Adult Influenza Vaccine Price, 2020 – 2021 Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation Table 7–1: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020 Table 7–2: Total Percentage of Influenza Vaccines Released by Week,2018 – 2019 Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018 Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017 Table 7–5: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016 Table 7–6: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015 Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2020 Table 9–1: Influenza Virus Testing Methods Table 10–1: Distribution of Influenza Vaccination Table 12–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization Table 13–1: Merger & Acquisitions in the Influenza Vaccines Market Table 13–2: Collaboration Deal in the Influenza Vaccines Market Table 13–3: Licensing Agreement in the Influenza Vaccines Market Table 13–4: Exclusive Agreement in the Influenza Vaccines Market Table 13–5: Distribution Agreement in the Influenza Vaccines Market Table 14–1: BiondVax Pharmaceuticals Ltd. – Clinical Trials Table 16–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development Table 16–2: Seqirus Promising Influenza Vaccines in the Clinical Development Table 17–1: Novavax Promising Influenza Vaccines in the Clinical Development Table 17–2: Biondvax Promising Influenza Vaccines in the Clinical Development Table 17–3: Medicago Promising Influenza Vaccines in the Clinical Development Table 17–4: Moderna Promising Influenza Vaccines in the Clinical Development Table 17–5: Pneumagen Promising Influenza Vaccines in the Clinical Development Table 17–6: Altimmune Promising Influenza Vaccines in the Clinical Development Table 17–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development Table 17–8: FluGen Promising Influenza Vaccines in the Clinical Development Table 17–9: Imutex Promising Influenza Vaccines in the Clinical Development List of Figures: Figure 2–1: United States Influenza Vaccines Market (Million US$),2013 – 2019 Figure 2–2: United States Influenza Vaccines Market Forecast (Million US$),2020 – 2027 Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019 Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027 Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027 Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2020 Figure 10–1: United States Place of Influenza Vaccination for Children and Adults (Percent),2018 - 2019 Figure 16–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2019 Figure 16–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027 Figure 16–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2019 Figure 16–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027 Figure 16–5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 – 2019 Figure 16–6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027 Figure 16–7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2013 – 2019 Figure 16–8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027